Answer
Infusion-related reactions were the most common adverse reactions in clinical studies of velaglucerase alfa, occurring in 39.4% of patients.
Sources for this answer
- VPRIV 400 Units powder for solution for infusionTakeda UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 20Document updated
Sources checked